Most cited papers from Novocure (United States)

Novocure (United States)

What are the most cited papers from Novocure (United States)?

The most cited paper from Novocure (United States) is "NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality" (Roger Stupp et al., 2012), with 863 citations. Next come "Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells" (326) and "Tumor treating fields: a new frontier in cancer therapy" (195).

Published TypeFieldAccessCitations

Showing 50 of 65 papers. Every paper with more than 1 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality Roger Stupp et al. · European Journal of Cancer Open access	17 May 2012	863
2	Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells Moshe Giladi, Rosa S. Schneiderman, Tali Voloshin et al. · Scientific Reports Open access	11 Dec 2015	326
3	Tumor treating fields: a new frontier in cancer therapy Angela M. Davies, Uri Weinberg, Yoram Palti · Annals of the New York Academy of Sciences	9 May 2013	195
4	Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR -Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors Jörg Felsberg, Bettina Hentschel, Kerstin Kaulich et al. · Clinical Cancer Research Open access	29 Aug 2017	188
5	Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy Tali Voloshin, Noa Kaynan, Shiri Davidi et al. · Cancer Immunology Immunotherapy Open access	6 Mar 2020	180
6	Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells Moshe Giladi, Mijal Munster, Rosa S. Schneiderman et al. · Radiation Oncology Open access	Dec 2017	161
7	Alternating Electric Fields (Tumor-Treating Fields Therapy) Can Improve Chemotherapy Treatment Efficacy in Non-Small Cell Lung Cancer Both In Vitro and In Vivo Moshe Giladi, Uri Weinberg, Rosa S. Schneiderman et al. · Seminars in Oncology Open access	8 Sep 2014	135
8	Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial Matthew T. Ballo, Noa Urman, Gitit Lavy-Shahaf et al. · International Journal of Radiation OncologyBiologyPhysics Open access	23 Apr 2019	129
9	Five-year Clinical and Economic Outcomes Among Patients With Medically Managed Severe Aortic Stenosis Mary Ann Clark, Suzanne V. Arnold, Francis G. Duhay et al. · Circulation Cardiovascular Quality and Outcomes Open access	Sep 2012	116
10	Characterization and Management of Dermatologic Adverse Events With the NovoTTF-100A System, a Novel Anti-mitotic Electric Field Device for the Treatment of Recurrent Glioblastoma Mario E. Lacouture, Mary Elizabeth Davis, Grace Elzinga et al. · Seminars in Oncology Open access	22 Mar 2014	112
11	AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields) Anna Shteingauz, Yaara Porat, Tali Voloshin et al. · Cell Death and Disease Open access	19 Oct 2018	111
12	Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields Moshe Giladi, Rosa S. Schneiderman, Yaara Porat et al. · Pancreatology	4 Dec 2013	99
13	Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study Ignace B. Vergote et al. · Journal of Clinical Oncology Open access	31 Aug 2023	87
14	Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis Matthew T. Ballo, Patrick R. Conlon, Gitit Lavy-Shahaf et al. · Journal of Neuro-Oncology ReviewOpen access	26 Jul 2023	82
15	Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo Tali Voloshin, Mijal Munster, Roni Blatt et al. · International Journal of Cancer Open access	25 Aug 2016	77
16	A Pilot Study with Very Low-Intensity, Intermediate-Frequency Electric Fields in Patients with Locally Advanced and/or Metastatic Solid Tumors Marc Oliver Salzberg, Eilon David Kirson, Yoram Palti et al. · Onkologie	2008	68
17	NovoTTF™-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ system user study Aafia Chaudhry, Laura M. Benson, Michael Varshaver et al. · World Journal of Surgical Oncology Open access	11 Nov 2015	66
18	Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields) Yaara Porat, Moshe Giladi, Rosa S. Schneiderman et al. · Journal of Visualized Experiments Open access	4 May 2017	59
19	Clinical and economic outcomes after surgical aortic valve replacement in Medicare patients Mary Ann Clark, Duhay, Thompson et al. · Risk Management and Healthcare Policy Open access	Oct 2012	54
20	Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma Simon Khagi, Rupesh R Kotecha, Na Tosha Gatson et al. · The Oncologist Open access	14 Aug 2024	53
21	Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models Yelena Mumblat et al. · Lung Cancer Open access	27 Aug 2021	51
22	Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune ® System Adrian Kinzel, Michael Ambrogi, Michael Varshaver et al. · Clinical Medicine Insights Oncology Open access	2019	45
23	Modeling Tumor Treating Fields (TTFields) application in single cells during metaphase and telophase Cornelia Wenger, Moshe Giladi, Zéev Bomzon et al. Conference paper	Aug 2015	43
24	Tumor Treating Fields Technology: Alternating Electric Field Therapy for the Treatment of Solid Tumors Laura M. Benson · Seminars in Oncology Nursing Open access	6 Apr 2018	41
25	Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines Hila Fishman, Roni Monin, Eyal Dor-On et al. · Journal of Neuro-Oncology Open access	May 2023	32
26	Role of the PI3K/AKT signaling pathway in the cellular response to Tumor Treating Fields (TTFields) Anat Klein-Goldberg et al. · Cell Death and Disease Open access	27 Mar 2025	26
27	Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer Siddharth Mehra, Vanessa T. Garrido, Austin R. Dosch et al. · Cancer Research Communications Open access	24 Jun 2023	25
28	Treatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma Akshat Sarkari, Sophie Korenfeld, Karina Deniz et al. · eLife Open access	25 Oct 2023	18
29	Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement Jennifer Connelly, Adı́lia Hormigo, Nimish Mohilie et al. · BMC Cancer Open access	4 Nov 2016	18
30	Using computational phantoms to improve delivery of Tumor Treating Fields (TTFields) to patients Zéev Bomzon, Hadas Sara Hershkovich, Noa Urman et al. Conference paper	Aug 2016	18
31	A Current Review on the Role of Prebiotics in Colorectal Cancer Anna Shrifteylik, Morgan Maiolini, Matthew E. Dufault et al. · Biologics Open access	22 Aug 2023	17
32	Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma Joshua David Palmer, Gordon Vincent Chavez, Wesley E. Furnback et al. · Frontiers in Oncology Open access	2 Dec 2021	16
33	Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region Milan J. Anadkat, Mario E. Lacouture, Adam Friedman et al. · Frontiers in Oncology Open access	4 Jan 2023	15
34	Long-term survival, patterns of progression, and patterns of use for patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting Devon C. Riegel, Britta Lynn Bureau, Patrick R. Conlon et al. · Journal of Neuro-Oncology Open access	31 Mar 2025	14
35	Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic Na Tosha Gatson, Jill S. Barnholtz‐Sloan, Jan Drappatz et al. · Frontiers in Oncology Open access	7 May 2021	14
36	Local Ablative Therapies for Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer Vikram Jairam, Henry Soo-Min Park, Roy H. Decker · The Cancer Journal	Mar 2020	13
37	The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts Nancy Ann Oberheim-Bush, Wenyin Shi, Michael William McDermott et al. · Journal of Neuro-Oncology Book chapterOpen access	31 May 2022	12
38	Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective study Aseala I. Abousaud, Meagan Spencer Barbee, Christine C. Davis et al. · Therapeutic Advances in Medical Oncology Open access	2020	12
39	Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer Cheryl Ho, Angela M. Davies, Randeep S. Sangha et al. · Investigational New Drugs Open access	7 Sep 2013	10
40	Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors James Louis Rogers et al. · Journal of Neuro-Oncology Open access	Mar 2024	9
41	Real-world Evidence for Impact of Opioid Agonist Therapy on Nonfatal Overdose in Patients with Opioid Use Disorder during the COVID-19 Pandemic Kenneth Lee, Yue Zhao, Tazmin Merali et al. · Journal of Addiction Medicine Open access	11 Aug 2023	8
42	Tumor treating fields as novel combination partner in the multimodal treatment of head and neck cancer Sebastian Regnery, Henrik Franke, Thomas K Held et al. · Head & Neck Open access	5 Mar 2023	7
43	Improvements in survival for glioblastoma in the post-Stupp protocol era Mackenzie Price, Justin Low, Gordon Vincent Chavez et al. · Neuro-Oncology Open access	22 Jul 2025	6
44	LBA3 Tumor Treating Fields (TTFields) therapy plus XELOX chemotherapy for front line treatment of advanced unresectable gastroesophageal junction adenocarcinoma (GEJC) or gastric adenocarcinoma (GC): A multicenter phase II trial Jie Li, S. Cang, Y. Ling et al. · Annals of Oncology Open access	Nov 2022	6
45	The transcriptomic fingerprint of cancer response to Tumor Treating Fields (TTFields) Kerem Wainer-Katsir et al. · Cell Death Discovery Open access	10 Jul 2025	5
46	Tumor Treating Fields (TTFields) for Newly Diagnosed Glioblastoma in the Real World: A Systematic Review and Survival Meta-Analysis Matthew T. Ballo, Patrick R. Conlon, Gitit Lavy-Shahaf et al. · International Journal of Radiation OncologyBiologyPhysics Open access	29 Sep 2023	5
47	Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis Taymaa May et al. · Canadian Journal of Surgery Open access	27 Jun 2023	5
48	First steps to creating a platform for high throughput simulation of TTFields Hadas Sara Hershkovich, Zéev Bomzon, Cornelia Wenger et al. Conference paper	Aug 2016	5
49	Використання несолодженого ячменю в пивоварінні Sergii Loiko, Зоряна Миколаївна Романова · Proceedings of National Aviation University Open access	23 Nov 2018	4
50	Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting Yu Yang Soon, Wesley E. Furnback, Jin Kim et al. · JTO Clinical and Research Reports Open access	27 Sep 2023	3

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.